The invention relates to novel heterocyclic compounds of formula (I):(see formula I)in which R1 and R1a independently are an optionally substituted mono- orbicyclicsaturated, unsaturated or aromatic carbo- or heterocycle； D is O, NH or S； Wis CX orN； T and T' are CX, N or CR, with the proviso that T and T' are not both CR； Ris-C(=O)-N(R2)[C(R2)2]n R1a； X is H, Hal, A, OR2, N(R2)2, NO2, CN, COOR2,CON(R2)2,NR2COA, NR2SO2A, COR2 or SO2NR2； R2 is H, A, -[C(R3)2]n-Ar', -[C(R3)2]n-Het',-[C(R3)2]n-cycloalkyl, -[C(R3)2]-OR3, -[C(R3)2]n-COOA or -[C(R3)2]n N(R3)2； R3is Hor A； A is optionally branched and modified C1-10 alkyl； Ar' is optionallysubstitutedphenyl, naphthyl or biphenyl； Het' is an optionally substituted mono- orbicyclicsaturated, unsaturated or aromatic heterocycle； Hal is F, CI, Br or I, and nis 0, 1, 2or 3. Said compounds are SGK-inhibitors and can be used in the treatment ofSGK-related diseases and disorders such as diabetes, obesity, metabolicsyndrome(dyslipidemia), systemic and pulmonal hypertension, cardiovascular diseasesandrenal diseases, and generally for any kind of fibroses and inflammatoryprocesses.
